• 1.

    Catalano M, et al. Sodium levels and outcomes in patients with metastatic renal cell carcinoma receiving nivolumab. JAMA Netw Open 2023; 6:e2345185. doi: 10.1001/jamanetworkopen.2023.45185

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Schutz FA, et al. The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium. Eur Urol 2014; 65:723730. doi: 10.1016/j.eururo.2013.10.013

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Uppal NN, et al. Electrolyte and acid-base disorders associated with cancer immunotherapy. Clin J Am Soc Nephrol 2022; 17:922933. doi: 10.2215/CJN.14671121

  • 4.

    Workeneh BT, et al. Hyponatremia in the cancer patient. Kidney Int 2020; 98:870882. doi: 10.1016/j.kint.2020.05.015

Why Sodium Levels Might Matter for Patients with Advanced Kidney Cancer Treated with Nivolumab

Biruh T. Workeneh Biruh T. Workeneh, MD, FASN, is a professor of medicine in the Section of Nephrology at The University of Texas MD Anderson Cancer Center, Houston. Helbert Rondon-Berrios, MD, MS, FACP, FASN, FNKF, is a professor of medicine and Nephrology Fellowship Program Director in the Renal-Electrolyte Division at the University of Pittsburgh School of Medicine, PA.

Search for other papers by Biruh T. Workeneh in
Current site
Google Scholar
PubMed
Close
and
Helbert Rondon-Berrios Biruh T. Workeneh, MD, FASN, is a professor of medicine in the Section of Nephrology at The University of Texas MD Anderson Cancer Center, Houston. Helbert Rondon-Berrios, MD, MS, FACP, FASN, FNKF, is a professor of medicine and Nephrology Fellowship Program Director in the Renal-Electrolyte Division at the University of Pittsburgh School of Medicine, PA.

Search for other papers by Helbert Rondon-Berrios in
Current site
Google Scholar
PubMed
Close
Restricted access
Save